Leukocyte Cell Derived Chemotaxin 2 (LECT2) is a secreted multifunctional cytokine mainly synthesized in the liver. It participates in immune regulation, inflammatory response and tissue remodelling by modulating leukocyte migration and activation. LECT2 takes part in pathological processes including liver fibrosis, metabolic disorders and tumour development. It mediates intercellular signal transduction and balances pro-inflammatory and anti-inflammatory effects under diverse physiological and pathological conditions. Abnormal LECT2 secretion disrupts tissue homeostasis and promotes the progression of chronic inflammatory lesions. LECT2 interacts with Lpa to affect lipid metabolism and inflammatory signalling cascades in circulation.Briefly, Lpa was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μL were then transferred to LECT2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-Lpa pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. Measured by its binding ability in a functional ELISA. When recombinant human LECT2 is immobilized at 2 μg/mL(100 μL/well), the concentration of Lpa that produces 50% optimal binding-response is found to be approximately0.018 μg/mL.